title: Promoter Methylation Analysis of IDH Genes in Human Gliomas.
abstract: Mutations in isocitrate dehydrogenase (IDH)-1 or -2 are found in the majority of WHO grade II and III astrocytomas and oligodendrogliomas, and secondary glioblastomas. Almost all described mutations are heterozygous missense mutations affecting a conserved arginine residue in the substrate binding site of IDH1 (R132) or IDH2 (R172). But the exact mechanism of IDH mutations in neoplasia is not understood. It has been proposed that IDH mutations impart a "toxic gain-of-function" to the mutant protein, however a dominant-negative effect of mutant IDH has also been described, implying that IDH may function as a tumor suppressor gene. As most, if not all, tumor suppressor genes are inactivated by epigenetic silencing, in a wide variety of tumors, we asked if IDH1 or IDH2 carry the epigenetic signature of a tumor suppressor by assessing cytosine methylation at their promoters. Methylation was quantified in 68 human brain tumors, including both IDH-mutant and IDH wildtype, by bisulfite pyrosequencing. In all tumors examined, CpG methylation levels were less than 8%. Our data demonstrate that inactivation of IDH function through promoter hypermethylation is not common in human gliomas and other brain tumors. These findings do not support a tumor suppressor role for IDH genes in human gliomas.
authors.affiliation: Discipline of Pathology, University of Sydney Sydney, NSW, Australia ; Department of Neuropathology, Royal Prince Alfred Hospital Sydney, NSW, Australia.
authors.forename: Simon
authors.initials: S
authors.lastname: Flanagan
authors.forename: Maggie
authors.initials: M
authors.lastname: Lee
authors.forename: Cheryl C Y
authors.initials: CC
authors.lastname: Li
authors.forename: Catherine M
authors.initials: CM
authors.lastname: Suter
authors.forename: Michael E
authors.initials: ME
authors.lastname: Buckland